Clinical trial · Observational
Intermediate and Long Term Vascular Effects of Cisplatin in Patients With Testicular Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Chemotherapy drugs improve cancer survival but increase the risk of cardiovascular disease (CVD). VEGF inhibitors (VEGFI) cause severe hypertension, while cisplatin appears pro-thrombotic. Hence while cancer survival may improve, this is at the risk of potentially severe CVD and associated morbidity. Mechanisms underlying the cardiovascular toxicities of VEGFI and cisplatin are unknown, but effects on vascular function may be important. The INTELLECT study will phenotype the endothelial effects of VEGFI and cisplatin using a variety of methods.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiovascular Diseases | — | UNRESOLVED | — |
| Cardiovascular Risk Factor | — | UNRESOLVED | — |
| Testicular Cancer | Malignant Testicular Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- venous occlusion plethysmography assessment of endothelial function
- timeFrame
- 8 weeks
- description
- expressed as ml per 100 ml of forearm volume per minute
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of stage 1 low-risk germ cell testicular cancer treated with orchidectomy, or IGCCC good or intermediate prognosis metastatic testicular/retroperitoneal germ cell cancer treated with orchidectomy (and or retroperitoneal surgery) plus cisplatin based chemotherapy, 12 - 18 months or 5 - 7 years previously. * Aged between 18 and 50 years inclusive, at time of enrolment Exclusion Criteria: * Unable to provide written, informed consent * Unable or unwilling to attend for investigations * Current active involvement in a clinical trial * Those receiving drug treatment for any vascular disease: o Including hypertension, hyperlipidaemia, cerebrovascular disease, ischaemic heart disease or heart failure * Asthma * Chronic obstructive pulmonary disease * Diabetes mellitus * Arial fibrillation/flutter * Oral anticoagulation therapy * Cigarette smoker or tobacco use * Recreational drug use * Ongoing inflammatory, infective or autoimmune disease * Other malignant disease diagnosed in previous 7 years * Previous venous or arterial thrombotic/thromboembolic event
References
Publications (1)
- DERIVEDCameron AC, McMahon K, Hall M, Neves KB, Rios FJ, Montezano AC, Welsh P, Waterston A, White J, Mark PB, Touyz RM, Lang NN. Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With Testicular Cancer. JACC CardioOncol. 2020 Sep;2(3):443-455. doi: 10.1016/j.jaccao.2020.06.004. PMID 33043304